Heartbeam, INC 10-Q quarterly reports

HeartBeam, Inc. reports continued losses and significant cash burn, raising going concern doubts, despite FDA clearance for its HeartBeam System and progress on 12L ECG synthesis software.

HeartBeam, Inc. reported increased net losses and cash burn, raising substantial doubt about its ability to continue as a going concern, despite recent FDA clearances and successful capital raises.

HeartBeam, Inc. announces its Q1 2025 financial results, showcasing progress in FDA clearances and strategic partnerships aimed at enhancing its cardiac monitoring solutions.

HeartBeam Inc.'s Q3 2024 report reveals increased R&D spending, a net loss, and concerns about the company's ability to continue as a going concern without additional funding.

HeartBeam, Inc. reported its second quarter 2024 financial results, highlighting increased R&D spending and progress towards FDA clearance for its cardiac monitoring technology.

HeartBeam, Inc. reported its Q1 2024 financial results, highlighting increased R&D spending and progress towards FDA clearance for its AIMIGo device.